Traws Pharma Inc (TRAW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Traws Pharma Inc (TRAW) has a cash flow conversion efficiency ratio of -0.883x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.01 Million) by net assets ($4.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Traws Pharma Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Traws Pharma Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Traws Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Traws Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Traws Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Altheora SA
PA:ALORA
|
0.089x |
|
Techgen Metals Ltd
AU:TG1
|
-0.102x |
|
Trinity Freehold & Leasehold PRP Fund
BK:TNPF
|
0.002x |
|
ARIP Public Company Limited
BK:ARIP
|
0.160x |
|
Haidemenos S.A.
AT:HAIDE
|
0.043x |
|
Loyal Solutions AS
ST:LOYAL
|
0.017x |
|
Fab-Form Industries Ltd.
V:FBF
|
0.059x |
|
Swift Tv Ltd
AU:STV
|
-0.178x |
Annual Cash Flow Conversion Efficiency for Traws Pharma Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Traws Pharma Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Traws Pharma Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-31.63 Million | $-29.79 Million | 0.942x | +156.06% |
| 2023-12-31 | $10.67 Million | $-17.93 Million | -1.680x | -191.93% |
| 2022-12-31 | $28.31 Million | $-16.29 Million | -0.576x | -36.22% |
| 2021-12-31 | $46.12 Million | $-19.49 Million | -0.423x | +88.69% |
| 2020-12-31 | $6.17 Million | $-23.07 Million | -3.737x | -107.62% |
| 2019-12-31 | $11.57 Million | $-20.83 Million | -1.800x | +57.28% |
| 2018-12-31 | $5.39 Million | $-22.70 Million | -4.213x | -292.10% |
| 2017-12-31 | $-10.86 Million | $-23.82 Million | 2.193x | +171.11% |
| 2016-12-31 | $5.13 Million | $-15.81 Million | -3.084x | -6.77% |
| 2015-12-31 | $10.84 Million | $-31.31 Million | -2.889x | -18.37% |
| 2014-12-31 | $23.62 Million | $-57.65 Million | -2.440x | -221.63% |
| 2013-12-31 | $80.90 Million | $-61.38 Million | -0.759x | -7255.60% |
| 2012-12-31 | $-158.31 Million | $1.63 Million | -0.010x | -110.08% |
| 2011-12-31 | $-138.42 Million | $-14.17 Million | 0.102x | -- |
About Traws Pharma Inc
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marbox… Read more